Garivulimab (BGB-A333) is a humanized IgG1-variant моноклональный антитело that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.